Biocatalysis 101: A Faster, Greener, and More Cost-Effective Approach to API Manufacturing

As pharmaceutical pipelines grow more complex and sustainability expectations rise, API manufacturing strategies are evolving. While traditional chemical synthesis remains a powerful and essential tool, it often involves tradeoffs in efficiency, waste generation, and overall cost of goods.

Biocatalysis in API manufacturing has emerged as a strategic alternative. By leveraging enzymes to drive highly selective reactions under mild process conditions, biocatalysis enables drug developers to accelerate timelines, reduce environmental impact, and improve process economics—without compromising quality or scalability.

This overview explains what biocatalysis is, why it matters in modern API manufacturing, and how it delivers measurable advantages in speed, sustainability, and cost.

What Is Biocatalysis in API Manufacturing?

Biocatalysis uses enzymes—or whole cells containing enzymes—to catalyze chemical reactions with exceptional specificity. These biological catalysts operate under mild process conditions, including:

Near-ambient temperatures

Atmospheric pressure

Neutral or near-neutral pH

Aqueous or predominantly aqueous solvent systems

Because enzymes are highly selective, they reduce reliance on extreme reagents, high-energy inputs, or harsh reaction environments. This makes biocatalysis particularly valuable for the efficient and selective synthesis of complex pharmaceutical molecules, especially those containing sensitive functional groups or multiple stereocenters.

In API manufacturing, biocatalysis is commonly applied to:

Generate chiral centers with high enantioselectivity

Perform regioselective oxidations or reductions,

Replace multistep chemical routes with simpler transformations

Improve yields and impurity profiles

As molecular complexity increases, enzymes often outperform traditional catalysts in both selectivity and efficiency.^1,5

Why Drug Developers Are Turning to Biocatalysis in API Manufacturing

Interest in biocatalysis is accelerating as drug molecules become more structurally complex, and regulatory scrutiny increases. Today’s development programs must balance speed to clinic, sustainability targets, and cost discipline – all while maintaining GMP compliance.

The advantages of biocatalysis in API manufacturing can be grouped into three core categories:

Faster development timelines

Greener and more sustainable processes

Lower total cost of goods

Faster Development and Manufacturing Timelines

High Selectivity Reduces Process Complexity

One of the most significant advantages of biocatalysis is selectivity. Enzymes are highly specific for their substrates, minimizing the formation of unwanted byproducts.

Higher selectivity leads to:

Fewer purification steps

Reduces downstream processing optimization

Cleaner impurity profiles

Faster route development during early phases.

For drug developers, these efficiencies translate into shorter timelines from route scouting to GMP manufacturing.²^,7

Mild Reaction Conditions Enable Rapid Scale-Up

Biocatalytic reactions typically operate at near-ambient temperatures and atmospheric pressure, often in aqueous systems and neutral pH ranges. Compared with high-temperature, high-pressure, or cryogenic chemical reactions, these mild operating conditions:

Reduce safety risks

Simplifies equipment requirements

Lower scale-up uncertainty

Improve technology transfer efficiency

As a result, manufacturing campaigns can be executed more efficiently—an important advantage for programs operating under aggressive clinical or commercial timelines.^,3^,5

Greener and More Sustainable API Manufacturing

Reduced Waste and Improved Atom Economy

Traditional synthetic routes often rely on protecting groups, stoichiometric reagents, and multistep sequences, all of which increase solvent consumption and waste generation.

Biocatalysis can:

Reduce solvent consumption

Decrease inorganic salt waste

Lower overall E-factor values

Improve atom economy

Simplify downstream waste treatment

In many cases, a single enzymatic transformation can replace multiple chemical steps, significantly improving process sustainability.⁴

Alignment With Regulatory and ESG Expectations

Regulatory agencies, investors, and pharmaceutical companies are placing greater scrutiny on environmental impact. Many organizations now operate under defined environmental, social, and governance (ESG) targets, including carbon reduction and greener supply chains.

Biocatalysis supports these goals by:

Lowering energy consumption

Reducing hazardous waste

Minimizing waste streams

Improving overall process safety

For drug developers, partnering with a CDMO that offers integrated biocatalytic capabilities can help meet sustainability commitments without compromising quality, scalability or regulatory compliance.^2,5

More Cost-Effective Manufacturing at Scale

Lower Raw Material and Energy Costs

Although enzyme development may require upfront investment, long-term economics are often favorable. Enzymes are typically used in small quantities and can frequently be reused or immobilized.

Biocatalytic routes can reduce:

Dependence on expensive chiral ligands

Precious metal catalysts

High-energy reaction conditions

Complex waste handling requirements

When evaluated across the full process lifecycle —including raw materials, energy consumption, waste treatment, and batch success rates—biocatalytic routes often outperform purely chemical alternatives on total cost of goods (COGs).^6,⁷

Improved Yields and Right-First-Time Manufacturing

High selectivity and cleaner reaction profiles contribute to:

Higher overall yields

Fewer process deviations

Lower impurity burdens

Reduce rework

For drug developers, this improved reliability lowers manufacturing risk, reduces batch failure costs, and strengthens supply chain resilience—especially critical for commercial APIs where margins and supply security are paramount.^6,7

When Does Biocatalysis Make Sense for Your API?

Biocatalysis is not a universal replacement for chemical synthesis. However, it is particularly valuable when:

Chiral purity is critical

Molecules are structurally complex

Sustainability or ESG pressures are high

Traditional routes struggle with yield or selectivity

Precious metal catalysts create cost or regulatory concerns

Early evaluation during route scouting allows development teams to determine whether biocatalysis can unlock meaningful advantages before key process decisions are finalized.³

Proven Biocatalysis Case Studies in Pharmaceutical API Manufacturing

Biocatalysis has moved beyond theoretical promise to deliver measurable impacts on commercial pharmaceutical manufacturing. A widely cited benchmark is the engineered transaminase process developed for sitagliptin, which replaced a rhodium-catalyzed asymmetric hydrogenation with a highly selective biocatalytic amination step—improving overall yield, eliminating precious metal use, reducing waste streams, and enhancing process sustainability at commercial scale.⁷ Beyond this example, industrial literature documents broad implementation of ketoreductases (KREDs), imine reductases (IREDs), and other engineered enzymes to replace classical metal-catalyzed reductions and stoichiometric chiral reagents in API intermediate synthesis.^5,6

These transformations enable high enantioselectivity under mild aqueous conditions while lowering E-factors and simplifying downstream purification.⁴ In parallel, modern advances in enzyme engineering and process integration—including continuous flow biocatalysis and multi-enzyme cascade systems—are demonstrating how biocatalysis can intensify manufacturing, shorten development timelines, and improve cost efficiency in GMP environments.²^,3

Collectively, these real-world applications confirm that enzyme-enabled synthesis is not a niche alternative, but a validated strategy for accelerating development and strengthening sustainable API production.

A Strategic Tool for Modern API Manufacturing

Biocatalysis has evolved from niche technology into a mainstream strategy in pharmaceutical manufacturing. For drug developers, it provides a proven pathway to accelerate development, reduce environmental impact, and improve cost efficiency – without compromising scalability or GMP compliance.

As API complexity increases and sustainability expectations continue to rise, biocatalysis will play an increasingly central role in building robust, future-ready manufacturing processes.

Ready to explore the benefits of biocatalysis for your API?

Reach out to SK pharmteco to discuss how our experts can support route evaluation, process development, and scalable manufacturing solutions tailored to your molecule and program goals.

References

U.T. Bornscheuer, et al., Engineering the Third Wave of Biocatalysis, Nature, 485, 185 (2012). doi.org/10.1038/nature11117

J. Woodley, Ensuring the Sustainability of Biocatalysis,  ChemSusChem, 15(9), e202102683 (2022). doi.org/10.1002/cssc.202102683

J.M. Woodley, New Horizons for Biocatalytic Science, Front. Catal., Sec. Biocatalysis, 2, (2022). doi.org/10.3389/fctls.2022.883161

R.A. Sheldon, The E Factor 25 Years On: The Rise of Green Chemistry and Sustainability, Green Chemistry, 1 (2017). doi.org/10.1039/C6GC02157

R.A. Sheldon and J. Woodley, Role of Biocatalysis in Sustainable Chemistry, Chem. Rev., 118(2), 801 (2018). doi.org/10.1021/acs.chemrev.7b00203

D.J. Pollard, et al., Biocatalysis for Pharmaceutical Intermediates: The Future is Now, Trends in Biotechnology, 25(2), 66 (2007). doi.org/10.1016/j.tibtech.2006.12.005

M.A. Huffman, et al., Design of an In Vitro Biocatalytic Cascade for the Manufacture of Sitagliptin, Science, 366(6461), 1255 (2019). doi.org/10.1126/science.aay8484

M.J. Takle, S.C. Cosgrove, and A.D. Clayton, Autonomous Optimization of Biocatalytic Reactions in Continuous Flow, Chem. Sci., 16, 18783 (2025). doi.org/10.1039/D5SC04249F

A.K. Gilio, et al., Practical Examples of Biocatalysis in Industry, Comptes Rendus Chimie, 28, 625 (2025). doi.org/10.5802/crchim.408

For those wanting information about quantitative improvements…

Engineered biocatalysts for challenging transformations in small molecule synthesis:
Recent reports highlight breakthroughs in using enzymes to perform reactions that were traditionally in the domain of organometallic or harsh chemical catalysis. For example, researchers have engineered enzymes to perform non-natural reactivity such as carbene and nitrene transfer and radical cyclizations – classes of reactions typically catalyzed by transition metals – now accessible via designed P450 or artificial enzyme platforms. These advances show the expanding reaction space for enzymes in complex chemical synthesis, including potential relevance to API intermediate synthesis.

Widespread adoption of biocatalytic steps across discovery, development, and commercial manufacture:
Industry reviews from 2025 indicate that biocatalysis has matured from a niche tool to a central component of small-molecule API production. Strategies now integrate AI-driven enzyme design, expanded substrate scope, and hybrid routes that combine biocatalysis with traditional organic synthesis. This has enabled enzymes to compete directly with classical metal catalysts for key steps such as stereoselective oxidations, reductions, and C–C bond formations in real manufacturing environments.

Transaminase replacement of metal catalysis in sitagliptin production:
The commercial production of sitagliptin remains one of the most cited examples of a traditional metal-catalysed asymmetric hydrogenation being replaced industrially with an engineered transaminase enzyme — achieving high enantiopurity and avoiding expensive catalysts and conditions. This milestone continues to motivate ongoing enzyme development across other drug routes.

Expanded commercial-scale enzymatic reductions and aminotransfer steps:
Large suppliers and specialist enzyme technology providers reported significant uptake of enzyme systems (e.g., ketoreductases, transaminases, imine reductases) for enantioselective reductions and aminations of pharmaceutical intermediates. These enzymatic steps often replace classical stoichiometric chiral reagents or metal catalysts with milder, aqueous-compatible processes compatible with large throughput.

Continuous and flow biocatalysis for manufacturing intensification:
Recent sustainable process work has shown how enzymes can be integrated into continuous flow platforms — making multi-enzyme cascades both more productive and greener compared with batch chemical routes. Entire sequences that formerly required heavy-metal catalysts and protecting-group strategies are increasingly feasible with immobilized enzymes under continuous conditions.

Case study lessons from industrial biocatalysis training and roundtables:
Educational case studies for small molecule APIs highlight specific enzymatic alternatives to traditional catalytic pathways, such as reductive amination using transaminases and imine reductases in place of classical hydrogenations or borohydride reductions. These documented cases, while not tied to a single company’s product, reflect real, plausible replacements for traditional catalysts being implemented across R&D and into production.

Industry commitment to enzyme catalysis integration:
Service providers and biotech partners (e.g., firms focused on enzyme engineering) are actively supporting pharma companies in replacing resource-intensive chemical-catalyst steps with tailored biocatalysts and scaling these into commercial APIs. Their offerings emphasize reducing reliance on precious metals and enabling complex transformations previously difficult with conventional catalysis.